Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 12, 2009, Pages 1175-1184

  Scott, Nicola J A ^a   Ellmers, Leigh J ^a   Lainchbury, John G ^b   Maeda, Nobuyo ^c   Smithies, Oliver ^c   Richards, A Mark ^a   Cameron, Vicky A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Akt1; Atrial natriuretic peptide; Calcineurin A; Cardiac hypertrophy; Connexin 43; Gene expression; Heart development; Npr1; Transcription factor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CONNEXIN 43; HORMONE RECEPTOR; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2A; MYOCYTE ENHANCER FACTOR 2C; NATRIURETIC PEPTIDE RECEPTOR 1; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMEGALY; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GENE EXPRESSION; HEART DEVELOPMENT; HEART HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREGNANCY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL; WILD TYPE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BLOTTING, WESTERN; CARDIOMEGALY; CONNEXIN 43; EMBRYO, MAMMALIAN; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEART; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, KNOCKOUT; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, ATRIAL NATRIURETIC FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS;

MUS;

EID: 71849118237     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.09.009     Document Type: Article

References (42)

1. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., and Frampton C. Renal, endocrine and haemodynamic effects of human brain natriuretic peptide in normal men. J. Clin. Endocrinol. Metab. 76 (1993) 91-96
2. Espiner E.A., Richards A.M., Yandle T.G., and Nicholls M.G. Natriuretic hormones. Endocrinol. Metab. Clin. N. Am. 24 (1995) 481-509
3. Lang C.C., Choy A.M.J., Turner K., Tobin R., Coutie W., and Struthers A.D. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J. Hypertens. 11 (1993) 737-741
4. Jaekle R.K., Sheikh A.U., Berry D.D., Washburn L., and Rose J.C. Hemodynamic and hormonal responses to atrial distension in the ovine fetus. Am. J. Obstet. Gynecol. 173 (1995) 694-701
5. Cameron V.A., Aitken G.D., Ellmers L.J., Kennedy M.A., and Espiner E.A. The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: temporal changes in embryos and placenta. Endocrinology 137 (1996) 817-824
6. Kingdom J.C., Jardine A.G., Doyle J., Connell J.M., Gilmore D.H., and Whittle M.J. Atrial natriuretic peptide in the fetus. BMJ (Clinical research ed 298 (1989) 1221-1222
7. Christoffels V.M., Habets P.E., Franco D., Campione M., de Jong F., Lamers W.H., Bao Z.Z., Palmer S., Biben C., Harvey R.P., and Moorman A.F. Chamber formation and morphogenesis in the developing mammalian heart. Dev. Biol. 223 (2000) 266-278
8. Zeller R., Bloch K.D., Williams B.S., Arceci R.J., and Seidman C.E. Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis. Genes Dev. 1 (1987) 693-698
9. Day M.L., Schwartz D., Wiegand R.C., Stockman P.T., Brunnert S.R., Tolunay H.E., Currie M.G., Standaert D.G., and Needleman P. Ventricular atriopeptin: unmasking of mRNA and peptide synthesis by hypertrophy or dexamethasone. Hypertension 9 (1987) 485-491
10. Lattion A.L., Michel J.B., Arnauld E., Corvol P., and Soubrier F. Myocardial recruitment during ANF mRNA increase with volume overload in the rat. Am. J. Physiol. 251 (1986) H890-H896
11. Takayanagi R., Imada T., and Inagami T. Synthesis and presence of atrial natriuretic factor in rat ventricle. Biochem. Biophys. Res. Commun. 142 (1987) 483-488
12. Oliver P.M., Fox J.E., Kim R., Rockman H.A., Kim H.S., Reddick R.L., Pandey K.N., Milgram S.L., Smithies O., and Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14730-14735
13. Oliver P.M., John S.W., Purdy K.E., Kim R., Maeda N., Goy M.F., and Smithies O. Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2547-2551
14. Knowles J.W., Esposito G., Mao L., Hagaman J.R., Fox J.E., Smithies O., Rockman H.A., and Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. 107 (2001) 975-984
15. Kuhn M., Holtwick R., Baba H.A., Perriard J.C., Schmitz W., and Ehler E. Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart 87 (2002) 368-374
16. -) mice with cardiac hypertrophy and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H707-H714
17. Lopez M.J., Garbers D.L., and Kuhn M. The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J. Biol. Chem. 272 (1997) 23064-23068
18. Molkentin J.D., and Dorn II I.G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63 (2001) 391-426
19. Vellaichamy E., Sommana N.K., and Pandey K.N. Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochem. Biophys. Res. Commun. 327 (2005) 106-111
20. Walther T., Stepan H., and Faber R. Dual natriuretic peptide response to volume load in the fetal circulation. Cardiovasc. Res. 49 (2001) 817-819
21. Nimrod C., Keane P., Harder J., Davies D., Kondo C., Takahashi Y., Wong T., Maloney J., and Nicholson S. Atrial natriuretic peptide production in association with nonimmune fetal hydrops. Am. J. Obstet. Gynecol. 159 (1988) 625-628
22. Itoh H., Sagawa N., Hasegawa M., Okagaki A., Inamori K., Ihara Y., Mori T., Suga S., Mukoyama M., Shirakami G., et al. Brain natriuretic peptide levels in the umbilical venous plasma are elevated in fetal distress. Biol. Neonate 64 (1993) 18-25
23. Ellmers L.J., Scott N.J., Piuhola J., Maeda N., Smithies O., Frampton C.M., Richards A.M., and Cameron V.A. Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J. Mol. Endocrinol. 38 (2007) 245-257
24. Gundersen H.J., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147 (1987) 229-263
25. Dragunow M., Cameron R., Narayan P., and O'Carroll S. Image-based high-throughput quantification of cellular fat accumulation. J. Biomol. Screen. 12 (2007) 999-1005
26. Graham E.S., Ball N., Scotter E.L., Narayan P., Dragunow M., and Glass M. Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 281 (2006) 29085-29095
27. Lopez M.J., Wong S.K., Kishimoto I., Dubois S., Mach V., Friesen J., Garbers D.L., and Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378 (1995) 65-68
28. Soma H., Yoshida K., Mukaida T., and Tabuchi Y. Morphologic changes in the hypertensive placenta. Contrib. Gynecol. Obstet. 9 (1982) 58-75
29. Martyn C.N., Barker D.J., Jespersen S., Greenwald S., Osmond C., and Berry C. Growth in utero, adult blood pressure, and arterial compliance. Br. Heart J. 73 (1995) 116-121
30. Xiong X., Mayes D., Demianczuk N., Olson D.M., Davidge S.T., Newburn-Cook C., and Saunders L.D. Impact of pregnancy-induced hypertension on fetal growth. Am. J. Obstet. Gynecol. 180 (1999) 207-213
31. Di Nicolantonio R., Koutsis K., and Wlodek M.E. Fetal versus maternal determinants of the reduced fetal and placental growth in spontaneously hypertensive rats. J. Hypertens. 18 (2000) 45-50
32. Leu M., Ehler E., and Perriard J.C. Characterisation of postnatal growth of the murine heart. Anat. Embryol. (Berl) 204 (2001) 217-224
33. Kishimoto I., Rossi K., and Garbers D.L. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2703-2706
34. Horsthuis T., Houweling A.C., Habets P.E., de Lange F.J., el Azzouzi H., Clout D.E., Moorman A.F., and Christoffels V.M. Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ. Res. 102 (2008) 849-859
35. Li Y., Kishimoto I., Saito Y., Harada M., Kuwahara K., Izumi T., Takahashi N., Kawakami R., Tanimoto K., Nakagawa Y., Nakanishi M., Adachi Y., Garbers D.L., Fukamizu A., and Nakao K. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 106 (2002) 1722-1728
36. McMullen J.R., and Jennings G.L. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol. 34 (2007) 255-262
37. Porrello E.R., Bell J.R., Schertzer J.D., Curl C.L., McMullen J.R., Mellor K.M., Ritchie R.H., Lynch G.S., Harrap S.B., Thomas W.G., and Delbridge L.M. Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 (2009) R672-R680
38. Rigor D.L., Bodyak N., Bae S., Choi J.H., Zhang L., Ter-Ovanesyan D., He Z., McMullen J.R., Shioi T., Izumo S., King G.L., and Kang P.M. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function. Am. J. Physiol. Heart Circ. Physiol. 296 (2009) H566-H572
39. Severs N.J., Coppen S.R., Dupont E., Yeh H.I., Ko Y.S., and Matsushita T. Gap junction alterations in human cardiac disease. Cardiovasc. Res. 62 (2004) 368-377
40. Eckardt D., Kirchhoff S., Kim J.S., Degen J., Theis M., Ott T., Wiesmann F., Doevendans P.A., Lamers W.H., de Bakker J.M., van Rijen H.V., Schneider M.D., and Willecke K. Cardiomyocyte-restricted deletion of connexin43 during mouse development. J. Mol. Cell. Cardiol. 41 (2006) 963-971
41. Beauchamp P., Choby C., Desplantez T., de Peyer K., Green K., Yamada K.A., Weingart R., Saffitz J.E., and Kleber A.G. Electrical propagation in synthetic ventricular myocyte strands from germline connexin43 knockout mice. Circ. Res. 95 (2004) 170-178
42. Danik S.B., Liu F., Zhang J., Suk H.J., Morley G.E., Fishman G.I., and Gutstein D.E. Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ. Res. 95 (2004) 1035-1041